Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica

JAMA Neurology

Volumn 70, Issue 3, 2013, Pages 390-393

  Kieseier, Bernd C ^a   Stüve, Olaf ^c,d   Dehmel, Thomas ^a   Goebels, Norbert ^a   Leussink, Verena I ^e   Mausberg, Anne K ^a   Ringelstein, Marius ^a   Turowski, Bernd ^b   Aktas, Orhan ^a   Antoch, Gerald ^b   Hartung, Hans Peter ^a  

^a Boston University Medical Campus   (United States)

^b Diagnostic and Interventional Radiology   (United States)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AQUAPORIN 4; CORTICOSTEROID; INTERLEUKIN 6; METHYLPREDNISOLONE; MITOXANTRONE; RITUXIMAB; STAT3 PROTEIN; TOCILIZUMAB;

ADULT; ARTICLE; CASE REPORT; DISABILITY; DRUG EFFECT; DRUG MEGADOSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAPLEGIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; QUADRIPLEGIA; RELAPSE; THERAPY RESISTANCE;

EID: 84874859809     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.668     Document Type: Article

References (10)

1. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805-815.
2. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes antiaquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A. 2011;108(9):3701-3706.
3. Uzawa A, Mori M, Sato Y, Masuda S, Kuwabara S. CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse. J Neurol Neurosurg Psychiatry. 2012;83(3):339-340.
4. Jones G, Ding C. Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2010;3:81-89.
5. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485-1489.
6. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361(9):888-898.
7. Wang HH, Dai YQ, QiuW, et al. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci. 2011;18(10):13131317.
8. Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, et al. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol. 2012;72(1):53-64.
9. Kleiter I, Hellwig K, Berthele A, et al Neuromyelitis Optica Study Group. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012; 69(2):239-245.
10. Zhang H, Bennett JL, Verkman AS. Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol. 2011; 70(6):943-954.